2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.
Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.
In the trial, patients who were previously treated with platinum-based chemotherapy and a PD-1/PD-L1 inhibitor and those who had not received platinum-containing chemotherapy or who are ineligible for cisplatin received enfortumab vedotin, an antibody-drug conjugate that targets Nectin-4, explains Sonpavde.
Results from the trial showed a high objective response rate of 44%. Moreover, responses were reported irrespective of prior treatment with platinum-based chemotherapy or PD-1/PD-L1 inhibitors. Additionally, the median duration of response was 7.6 months.
Encouragingly, investigators also reported complete responses in 12% of patients and robust responses in patients with liver metastases. Going forward, Sonpavde hopes enfortumab vedotin will be approved for clinical use in this patient population.